SequelSEC

Estrella Immunopharma, Inc. ESLA

Biological Products, (No Diagnostic Substances) · CIK 0001844417 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$13.06M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

Estrella Immunopharma, Inc. (ESLA) reported net income of -$13.06M for the fiscal year ended 2025-12-31. This page shows 5 annual periods of income statement, balance sheet and cash flow figures normalized from Estrella Immunopharma, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Estrella Immunopharma, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-06-302023-06-302022-12-312021-12-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$13.06M-$7.31M-$11.11M-$1.57M-$249.15K
Net income-$13.06M-$7.31M-$11.11M-$996.10K-$247.72K
Research & development$10.25M$4.11M$10.45MUnavailableUnavailable
Weighted-average diluted sharesshares 36.82Mshares 27.10MUnavailableUnavailableshares 1.18M
Pretax income-$13.06M-$7.31M-$11.11M-$915.46K-$247.72K
Income tax expense$838$1.62KUnavailable$80.65K$0
Diluted EPS$-0.35$-0.27$-36.35UnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$2.81M$3.20M$663.19KUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Estrella Immunopharma, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-06-302023-06-302022-12-312021-12-31
Cash & equivalents$1.38M$4.17M$2.48M$40.80K$478.87K
Total assets$3.18M$4.45M$3.03M$9.72M$45.80M
Current assets$1.68M$4.45M$2.75M$52.43K$616.03K
Total liabilities$13.54M$180.70K$9.77M$2.65M$1.62M
Current liabilities$13.54M$180.70K$9.76M$1.07M$73.15K
Total equity incl. NCI-$10.37M$4.27M-$11.74M-$6.48M-$1.01M
Temporary (mezzanine) equityUnavailableUnavailable$9.75M$9.33M$45.19M
InventoryUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailable$273.07KUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payableUnavailableUnavailableUnavailableUnavailableUnavailable

Cash flow

Estrella Immunopharma, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-06-302023-06-302022-12-312021-12-31
Operating cash flow-$1.79M-$16.07M-$1.34M-$1.04M-$316.16K
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flowUnavailable$4.96M-$273.07K$36.17M-$45.19M
Financing cash flow$2.25M$12.79MUnavailable-$35.56M$45.98M
Net change in cashUnavailableUnavailableUnavailable-$438.07K$478.87K
Stock-based compensation$618.97K$1.19M$409.60KUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Estrella Immunopharma, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-06-302023-06-302022-12-312021-12-31
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio0.12x24.65x0.28x0.05x8.42x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ESLA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-18View SEC filing
10-K · Filed 2026-03-18View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-14View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Reconciliation checks needing review

2 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2023-06-30

Difference 4752003 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.

balance equationreview2022-12-31

Difference 4220094 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.